Fluoxetine + Dextromethorphan for body dysmorphic disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 May 2021: Trial registered, NCT04899687
  2. 20 Jan 2022: Trial started, NCT04899687

The trials

NCT04899687: Study of Dextromethorphan in OCD and Related Disorders

State
Under way
Phase
Phase 2
People
60 planned
Started
20 Jan 2022
Primary completion
1 Apr 2027
Arms
Group A: fluoxetine then fluoxetine plus dextromethorphan, Group B: fluoxetine plus dextromethorphan then fluoxetine
Results
None posted
  1. 24 May 2021: Trial registered
  2. 20 Jan 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.